Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges including price cuts and a missed trial endpoint for its next-gen drug. Lilly is expanding aggressively with acquisitions and international growth, while Novo focuses on restructuring and managing pricing pressures. The competition now centers on oral GLP-1 drugs, with investors favoring Lilly's growth story but watching Novo's potential turnaround closely.
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
About 30 million Americans use GLP-1 drugs, which chemically suppress appetite and reduce fast food demand by 27-30%. This structural shift benefits companies like Amazon, which is expanding its pharmacy and delivery services; Eli Lilly, leading with...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
The investor highlights NVIDIA's massive revenue growth and cash flow, boosted by AI demand and strong capital returns. Eli Lilly impresses with high revenue growth driven by key drugs like Mounjaro and Foundayo, despite pricing pressures. Johnson & ...
Ahead of its mega-IPO, SpaceX revealed healthcare ambitions in its SEC filing, highlighting Starlink's role in improving remote healthcare access in underserved areas. The company also envisions manufacturing pharmaceuticals in orbit, leveraging micr...
